Mesenchymal Stem Cells in the Treatment of Subjects with Advanced Chronic Obstructive Pulmonary Disease (COPD)

 A currently recruiting study being done by The Mayo Clinic that seeks into understanding the effects of mesenchymal stem cell therapy in patients with advanced chronic pulmonary disease (COPD). It is a single group assignment with the procedure including a single dose of MSC’s intravenously. The only primary outcome is to measure adverse effects.

https://clinicaltrials.gov/ct2/show/NCT04047810?id=NCT04047810+OR+NCT02216630+OR+NCT02341326+OR+NCT01110252+OR+NCT03044431+OR+NCT00683722+OR+NCT02348060+OR+NCT03040674&draw=2&rank=1&load=cart

 

An Observational Outcomes Study for Autologous Cell Therapy Among Patients with COPD and Interstitial Lung Disease

 A recruiting study being done by the Lung Institute that hopes to increase the advancement of stem cell therapy for COPD patients. For this particular study, the researchers say they “aim to confirm the safety of autologous cell therapy, explore the effects of autologous cell therapy treatment on pulmonary function, and to describe the anecdotal quality of life changes of patients following treatment…”. This is a follow-up study to a similar already completed trial.

This trial is an observational cohort study including the harvesting of stem cells from either bone marrow or peripheral blood, and same day peripheral circulation treatment to return the stem cells back to the body after processing. The outcome measures include estimating quality of life for up to six months, changes in MMRC scale, and change in FEV1 from baseline.

https://clinicaltrials.gov/ct2/show/NCT03040674?id=NCT02216630+OR+NCT02341326+OR+NCT01110252+OR+NCT03044431+OR+NCT00683722+OR+NCT02348060+OR+NCT03040674&draw=2&rank=2&load=cart

 

Outcome Data of Adipose Stem Cells to Treat Chronic Obstructive Pulmonary Disease

 A recruiting study being done by StemGenex that wants to determine the impact that treatment with stromal vascular fraction has on patients suffering from COPD. It is an observational study with the outcomes including measuring quality of life, breathing comfort, fatigue, and emotional function.

https://clinicaltrials.gov/ct2/show/NCT02348060?id=NCT02216630+OR+NCT02341326+OR+NCT01110252+OR+NCT03044431+OR+NCT00683722+OR+NCT02348060&draw=2&rank=2&load=cart

 

Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD

 This recruiting study being done by Weill Medical College of Cornell University focuses on the SAE cells in the lungs that obstruct airways for early COPD patients. Fibroblast growth factor receptor 2 (FGFR2) is essential for the stability of lung functioning in the SAE; which can be depleted from cigarette smoking. In this study, researchers will evaluate and compare the SAE and lungs of smokers versus nonsmokers.

This is an observational case-control study that will study whether cells in the SAE of smokers have reduced capacity to generate normally, and to also initiate airway branching and repair in response to injury. This study also aims to test their hypothesis that FGFR2 signaling is necessary for normal SAE stem cell function and suppression of it caused by inhibitors leads to altered cell function similar to COPD.

https://clinicaltrials.gov/ct2/show/NCT02341326?id=NCT02216630+OR+NCT02341326+OR+NCT01110252+OR+NCT03044431+OR+NCT00683722&draw=2&rank=2&load=cart

Autologous Stem Cell Treatment for Chronic Lung Disease Study

 A completed study from the Lung Institute that aims to describe the safety and efficacy of autologous stem cell treatment while also seeking out long term effects of treatment, and measuring quality of life. It is an observational study including harvesting stem cells from either the peripheral blood or the patient’s bone marrow, and returning cells later that same day after processing (similar to their recruiting study mentioned earlier).

This study came back with results. Of their 207 participants, 148 completed the study all the way to its final endpoint. Most of the patients underwent the transfusion of peripheral blood, while the other patients used stem cells from their bone marrow. The patients did a questionnaire whereby on a scale of 0-6, the mean score was 3.6 of how severe their symptoms were after treatment and quality of life. The study reports that there were no adverse events that happened after treatment, no deaths caused by treatment, and only 10 patients reported non-serious adverse events after treatment not caused by treatment.

This study shows great improvement for treating COPD patients; the researchers believe this study proves it is a viable source of treatment and more studies should be done to confirm it.

https://clinicaltrials.gov/ct2/show/results/NCT03044431?id=NCT02216630+OR+NCT01110252+OR+NCT03044431+OR+NCT00683722&draw=2&rank=1&load=cart

 

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

 This is a completed study done by Kimera Society Inc. that uses adipose-derived stem cells in treatment for COPD patients. The researches aim to investigate the “immunosuppressive potential of the non-manipulated non-cultured stromal vascular fraction obtained via liposuction”.

The procedure includes extracting 100cc of fat from each patient, isolating the stem cells, and delivering them back to the body intravenously. The outcome measures include monitoring the decline of forced evacuation volume (FEV1) and the number of adverse events post treatment for up to 12 months. The results of this experiment have not yet been posted.

https://clinicaltrials.gov/ct2/show/NCT02216630?id=NCT02216630+OR+NCT01110252+OR+NCT00683722&draw=2&rank=1&load=cart